Research Progress of Adoptive Cell Immunotherapy in Cervical Cancer
ZHANG Lan-yue
SHEN Fu-jin
Abstract：Cervical cancer is one of the most common malignant tumors among women.The 5-year survival rate of recurrent or metastatic cervical cancer is only 17％and the clinical treatment is very tricky.Programmed death-1(PD-1)monoclonal antibody has been used as a first-line treatment for recurrent or metastatic cervical cancer.However,the bottlenecks for PD-1 monoclonal antibody monotherapy are relatively lower objective response rate and higher drug resistance rate,which limits its clinical application.Recently,adoptive cell immunotherapy altered the landscape of cancer immunotherapy,which achieved antitumor effects by infusing antitumor cells back to the body.Currently,there are mainly three types of adoptive cell immunotherapy including tumor-infiltrating lymphocyte,T-cell receptor-engineered T cells and chimeric antigen receptor T-cell.Relative studies have demonstrated the significant value of adoptive cell immunotherapy on improvement of survival and prognosis for patients with advanced cervical cancer.The principles,biological characteristics,applications and limitations for adoptive cell immunotherapy are summarized in the review.Optimizing the productive technology and being combined with other oncological treatment may supply new ideas for cervical cancer immunotherapy.
Keywords：Uterine cervical neoplasmsImmunotherapyAdoptive cell immunotherapyTumor-infiltrating lymphocyteT-cell receptor-engineered T cellChimeric antigen receptor T-cell
Publication Date：2024-06-15
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 253-257 )